Canaccord Genuity Reiterates Buy Rating on BioXcel Therapeutics (BTAI) Ahead of Top-Line RELEASE Phase 1b/2 Data
Tweet Send to a Friend
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $110.00 price target on BioXcel Therapeutics (NASDAQ: BTAI) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
